Home > News > pSivida Limited: Rights Issue to Fund Trials
May 2nd, 2006
pSivida Limited: Rights Issue to Fund Trials
Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced details of a Non-Renounceable Rights Issue offering one new ordinary share for every eight shares held at May 22 ("the Record Date") at an issue price of AU$0.60 per share. Capital raised from this Rights Issue will primarily fund the phase III clinical trials of Medidur(TM) for the treatment of Diabetic Macular Edema (DME), and phase IIa clinical trials of our lead BioSilicon(TM) product, BrachySil(TM) which is being developed for the treatment of inoperable pancreatic cancer.
Source:
businesswire
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over 14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||